Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Jagsonpal Pharmaceuticals
Start SIPJagsonpal Pharmaceuticals Investment Rating
-
Master Rating:
-
Jagsonpal Pharmaceuticals has an operating revenue of Rs. 236.71 Cr. on a trailing 12-month basis. An annual revenue growth of 6% is not great, Pre-tax margin of 15% is great, ROE of 16% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 200DMA and around 8% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 55 | 60 | 61 | 61 | 52 |
| Operating Expenses Qtr Cr | 50 | 52 | 48 | 54 | 52 |
| Operating Profit Qtr Cr | 5 | 9 | 13 | 6 | 1 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 1 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 2 | 2 | 3 | 0 | 0 |
| Net Profit Qtr Cr | 6 | 8 | 10 | 0 | 0 |
Jagsonpal Pharmaceuticals Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹350.72
- 50 Day
- ₹341.92
- 100 Day
- ₹339.16
- 200 Day
- ₹331.21
- 20 Day
- ₹347.7
- 50 Day
- ₹335.69
- 100 Day
- ₹336.03
- 200 Day
- ₹348.44
Jagsonpal Pharmaceuticals Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹368.59 |
| Second Resistance | ₹377.27 |
| Third Resistance | ₹384.59 |
| RSI | 63.36 |
| MFI | 80.67 |
| MACD Single Line | 5.28 |
| MACD | 6.48 |
| Support | |
|---|---|
| First Resistance | ₹352.59 |
| Second Resistance | ₹345.27 |
| Third Resistance | ₹336.59 |
Jagsonpal Pharmaceuticals Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 40,948 | 2,415,523 | 58.99 |
| Week | 30,375 | 1,842,827 | 60.67 |
| 1 Month | 31,674 | 1,690,741 | 53.38 |
| 6 Month | 32,702 | 1,538,298 | 47.04 |
Jagsonpal Pharmaceuticals Result Highlights
Jagsonpal Pharmaceuticals Synopsis
NSE-Medical-Diversified
Jagsonpal Pharma belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 236.71 Cr. and Equity Capital is Rs. 13.10 Cr. for the Year ended 31/03/2023. Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181.| Market Cap | 956 |
| Sales | 237 |
| Shares in Float | 0.81 |
| No of funds | 5 |
| Yield | 1.37 |
| Book Value | 6.02 |
| U/D Vol ratio | 1 |
| LTDebt / Equity | |
| Alpha | 0.08 |
| Beta | 0.77 |
Jagsonpal Pharmaceuticals
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 68.71% | 68.71% | 68.71% | 68.71% |
| Mutual Funds | ||||
| Foreign Portfolio Investors | 0.1% | 0.11% | 0.13% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 22.23% | 21.12% | 22.77% | 25.26% |
| Others | 8.96% | 10.06% | 8.39% | 6.03% |
Jagsonpal Pharmaceuticals Management
| Name | Designation |
|---|---|
| Mr. R P S Kochhar | Chairman Emeritus |
| Mr. Manish Gupta | Managing Director |
| Mr. Harsha Raghavan | Non Executive Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Ind. Non-Executive Director |
| Ms. Radhika Madhukar Dudhat | Ind. Non-Executive Director |
| Ms. Pallavi Dinodia Gupta | Ind. Non-Executive Director |
Jagsonpal Pharmaceuticals Forecast
Price Estimates
Jagsonpal Pharmaceuticals Corporate Action
Jagsonpal Pharmaceuticals FAQs
What is Share Price of Jagsonpal Pharmaceuticals ?
Jagsonpal Pharmaceuticals share price is ₹366 As on 05 June, 2023 | 01:10
What is the Market Cap of Jagsonpal Pharmaceuticals ?
The Market Cap of Jagsonpal Pharmaceuticals is ₹958.8 Cr As on 05 June, 2023 | 01:10
What is the P/E ratio of Jagsonpal Pharmaceuticals ?
The P/E ratio of Jagsonpal Pharmaceuticals is 39.7 As on 05 June, 2023 | 01:10
What is the PB ratio of Jagsonpal Pharmaceuticals ?
The PB ratio of Jagsonpal Pharmaceuticals is 6 As on 05 June, 2023 | 01:10